Organizations aim to advance precision oncology and biomarker-driven research.
Caris Life Sciences, an artificial intelligence (AI) TechBio company, announced that Sarah Cannon Research Institute (SCRI), an oncology research organization, has officially joined the Caris Precision Oncology Alliance (POA). According to Caris, the POA is a network of cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients.
"SCRI and Caris share a commitment to advancing therapies and expanding access to molecular diagnostic approaches for patients in the community," said Andrew McKenzie, PhD, VP, personalized medicine, SCRI; scientific director, Genospace. "We are pleased to join the Caris Precision Oncology Alliance and look forward to the opportunities to leverage comprehensive genomic data to inform clinical development strategies to improve outcomes for people facing cancer."
Reference: The Caris Precision Oncology Alliance Welcomes Sarah Cannon Research Institute. PR Newswire. October 26, 2023. Accessed October 27, 2023. https://www.prnewswire.com/news-releases/the-caris-precision-oncology-alliance-welcomes-sarah-cannon-research-institute-301968199.html
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.